Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03459820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prostate Cancer Patient Management With 18F-DCFPyL PET/CT

StatusEnrolling by Invitation
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2026 to Jun 2027
    • Study completion date: Jun 2027 to Jun 2028
    v8
  2. Primary completion date: Jun 2023 to Jun 2026
    • Study completion date: Jun 2024 to Jun 2027
    v7
  3. Phase: Phase 3 to Phase 2/3v6
  4. Primary completion date: Jun 2022 to Jun 2023
    • Study completion date: Jun 2023 to Jun 2024
    v5
  5. Study title expanded, about 2 wordsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Jun 2018 to Jun 22, 2018
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, single-arm, open-label, phase III trial in patients with biopsy-proven prostate cancer. Patients will receive regular standard of clinical care. The only study-specific procedures will the administration of 18F-DCFPyL followed by a PET/CT scan. Differences in theoretical optimal clinical management based on a review of clinical, biochemical and radiographic subject data before and after 18F-DCFPyL PET/CT imaging by a central panel of experts will be captured at study completion.
Trial Details
NCT Number NCT03459820
Lead Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov